Home › Funds › Almitas Capital LLC › AMLX
Almitas Capital LLC position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Almitas Capital LLC reported holding 974,881 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$17.5M, representing 4.20% of its reported portfolio and ranking #4 among its reported holdings. Almitas Capital LLC has disclosed AMLX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Almitas Capital LLC's AMLX position evolved
Almitas Capital LLC first disclosed a stake in AMLX in Q2 2024 at 1,903,851 shares (US$3.6M). The position peaked in Q1 2026 at 2,122,597 shares, worth US$29.5M. Across 9 filings, Almitas Capital LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 974,881 shares valued at US$17.5M — a reduction of -1,147,716 shares quarter over quarter.. Notable position changes include a 54% trim in Q2 2026 (shares rose 62% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 1.90M | $3.62M | New |
| Q3 2024 | 1.99M | $6.44M | Add |
| Q4 2024 | 2.03M | $7.68M | Add |
| Q1 2025 | 2.12M | $7.51M | Add |
| Q2 2025 | 2.12M | $13.61M | Hold |
| Q3 2025 | 2.12M | $28.85M | Hold |
| Q4 2025 | 2.12M | $25.64M | Hold |
| Q1 2026 | 2.12M | $29.50M | Hold |
| Q2 2026 | 974.88K | $17.51M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 50 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Commodore Capital LP 5.65M sh · $101.47M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Siren, L.L.C. 1.48M sh · $26.59M · Q2 2026
- Jones Hill Capital LP 894.06K sh · $16.06M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- HighVista Strategies LLC 386.08K sh · $6.93M · Q2 2026
- STEMPOINT CAPITAL LP 384.30K sh · $6.90M · Q2 2026
More on Almitas Capital LLC
FAQ
How long has Almitas Capital LLC held AMLX?
Almitas Capital LLC has disclosed AMLX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is Almitas Capital LLC's current position in AMLX?
As of Q2 2026, Almitas Capital LLC holds 974.88K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $17.51M, representing 4.20% of its reported portfolio and ranking #4.
Has Almitas Capital LLC been buying or selling AMLX?
In the latest 13F filing (Q2 2026), Almitas Capital LLC reduced its position in AMLX. The position peaked in Q1 2026 at 2.12M shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.